Sporadic inclusion body myositis and hereditary inclusion body myopathy

Journal of Clinical Neuromuscular Disease

Volumn 3, Issue 3, 2002, Pages 122-132

  Simmons, Zachary ^a,b   Towfighi, Javad ^a,b   Bromberg, Mark B ^a,c  

^a Penn State College of Medicine ^*

^b PENN STATE COLLEGE OF MEDICINE   (United States)

^c UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CHLORAMBUCIL; CYCLOSPORIN; IMMUNOGLOBULIN; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE;

ADULT; AGED; CELL VACUOLE; DIFFERENTIAL DIAGNOSIS; DISEASE COURSE; DOMINANT INHERITANCE; DRUG EFFICACY; ELECTRODIAGNOSIS; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOMODULATION; INCLUSION BODY MYOSITIS; MALE; MORPHOLOGICAL TRAIT; MOTOR NEURON DISEASE; MYOPATHY; NEUROMUSCULAR DISEASE; OXIDATIVE STRESS; PATHOGENESIS; POLYMYOSITIS; PRIORITY JOURNAL; RECESSIVE INHERITANCE; REVIEW;

EID: 0036198544     PISSN: 15220443     EISSN: None     Source Type: Journal    
DOI: 10.1097/00131402-200203000-00005     Document Type: Review

References (122)

1. Inclusion-body myositis
2. Myxovirus-like structures in a case of human chronic polymyositis
3. Inclusion body myositis and myopathies
4. New advances in inclusion-body myositis
5. Inclusion body myositis in Connecticut: Observations in 35 patients during an 8-year period
6. Epidemiology of inclusion body myositis in the Netherlands: A nationwide study
7. Inclusion body myositis
8. Inclusion body myositis: Clinical and pathological boundaries
9. Inclusion body myositis. Observations in 40 patients
10. Sporadic inclusion-body myositis and hereditary inclusion-body myopathies: Current concepts of diagnosis and pathogenesis
11. Inflammatory myopathies: Dermatomyositis, polymyositis, inclusion body myositis, and related diseases
12. Inclusion-body myositis: Newest concepts of pathogenesis and relation to aging and Alzheimer disease
13. Acquired myopathies
14. Inclusion body myositis presenting as treatment-resistant polymyositis
15. Polymyositis, dermatomyositis, and inclusion body myositis
16. Inclusion body myositis: New concepts
17. Mitochondrial abnormalities and peripheral neuropathy in inflammatory myopathy, especially inclusion body myositis
18. Electrophysiological spectrum of inclusion body myositis
19. Management of dysphagia in inclusion body myositis
20. Dysphagia in patients with inclusion body myositis
21. Dysphagia in inclusion body myositis
22. Inclusion body myositis with cricopharyngeus muscle involvement and severe dysphagia
23. Inclusion body myositis associated with progressive dysphagia: Treatment with cricopharyngeal myotomy
24. Autoimmune diseases and autoantibodies associated with sporadic inclusion body myositis
25. Magnetic resonance imaging of the forearm as a diagnostic aid in patients with inclusion body myositis
26. Presence of the anti-Jo-1 autoantibody excludes inclusion body myositis
27. Inclusion body myositis: An electrophysiologic study
28. A macro-EMG study in inclusion-body myositis; no evidence for a neurogenic component
29. The role of quantitative electromyography in inclusion body myositis
30. Quantitative electrophysiologic studies in sporadic inclusion body myositis
31. The immunopathologic and inflammatory differences between dermatomyositis, polymyositis and inclusion body myositis
32. The pathological diagnosis of specific inflammatory myopathies
33. Myopathia distalis tarda hereditaria
34. Distal myopathy: Electron microscopic and histochemical studies
35. Autosomal recessive distal muscular dystrophy-A new type of distal muscular dystrophy observed characteristically in Japan
36. Familial distal myopathy with rimmed vacuole and lamellar (myeloid) body formation
37. Tibial muscular dystrophy. Late adult-onset distal myopathy in 66 Finnish patients
38. Oculopharyngeal muscular dystrophy
39. Monoclonal antibody analysis of mononuclear cells in myopathies. I: Quantitation of subsets according to diagnosis and sites of accumulation and demonstration and counts of muscle fibers invaded by T cells
40. Monoclonal antibody analysis of mononuclear cells in myopathies. II: Phenotypes of autoinvasive cells in polymyositis and inclusion body myositis
41. Sporadic inclusion-body myositis and hereditary inclusion-body myopathies: Diseases of oxidative stress and aging?
42. Amyloid filaments in inclusion body myositis: Novel findings provide insight into nature of filaments
43. Enhanced detection of Congo-red-positive amyloid deposits in muscle fibers of inclusion body myositis and brain of Alzheimer's disease using fluorescence technique
44. Sporadic inclusion body myositis: Counts of different types of abnormal fibers
45. Twisted tubulofilaments of inclusion body myositis muscle resemble paired helical filaments of Alzheimer brain and contain hyperphosphorylated tau
46. Light- and electronmicroscopic localization of beta-amyloid protein in muscle biopsies of patients with inclusion-body myositis
47. β-amyloid precursor epitopes in muscle fibers of inclusion-body myositis
48. Use of antineurofilament antibody to identify paired-helical filaments in inclusion-body myositis
49. Rimmed vacuoles and the added value of SMI-31 staining in diagnosing sporadic inclusion body myositis
50. Immunocytochemical localization of ubiquitin in inclusion body myositis allows its light-microscopic distinction from polymyositis
51. Ubiquitin immunostaining and inclusion body myositis: Study of 30 patients with inclusion body myositis
52. Inclusion body myositis
53. Ragged red fibers in normal aging and inflammatory myopathy
54. Mitochondrial DNA deletions in muscle fibers in inclusion-body myositis
55. Multiple mitochondrial DNA deletions in sporadic inclusion body myositis: A study of 56 patients
56. Inclusion body myositis: Peripheral nerve involvement. Combined morphological and electrophysiological studies on peripheral nerves
57. Familial inclusion body myositis with histologically confirmed sensorimotor axonal neuropathy
58. Peripheral neuropathy associated with hereditary and sporadic inclusion body myositis: Confirmation by electron microscopy and morphometry
59. Inclusion body myositis: Explanation for poor response to immunosuppressive therapy
60. Inclusion body myositis mimicking motor neuron disease
61. Prognostic factors in sporadic inclusion body myositis
62. Disease progression in sporadic inclusion body myositis; observations in 78 patients
63. Safety and efficacy of strength training in patients with sporadic inclusion body myositis
64. Inclusion body myositis: A corticosteroid-resistant idiopathic inflammatory myopathy
65. Inclusion body myositis: Clinical, morphological, physiological and laboratory findings in 18 cases
66. The treatment of inclusion body myositis: A retrospective review and a randomized, prospective trial of immunosuppressive therapy
67. Anti-Jo-1 positive inclusion body myositis with a marked and sustained clinical improvement after oral prednisone
68. Inclusion body myositis: Analysis of 32 cases
69. Inclusion body myositis responding to longterm chlorambucil treatment
70. Total body irradiation not effective in inclusion body myositis
71. Mycophenolate (Cell-Cept) treatment of myasthenia gravis, chronic inflammatory polyneuropathy and inclusion body myositis
72. A case of inclusion body myositis with benign monoclonal gammopathy successfully responding to repeated immunoabsorption
73. Treatment of inclusion-body myositis with high-dose intravenous immunoglobulin
74. Inclusion body myositis: Treatment with intravenous immunoglobulin
75. Long-lasting effectiveness of intravenous immunoglobulin in a patient with inclusion-body myositis
76. Treatment of inclusion-body myositis with IVIg: A double-blind, placebo-controlled study
77. High-dose immunoglobulin therapy in sporadic inclusion body myositis: A double-blind, placebo-controlled study
78. A controlled study of intravenous immunoglobulin combined with prednisone in the treatment of IBM
79. Treatment of inflammatory myopathies
80. 'Rimmed vacuole myopathy' sparing the quadriceps: A unique disorder in Iranian Jews
81. Familial inclusion body myositis among Kurdish-Iranian Jews
82. Vacuolar myopathy sparing the quadriceps
83. The spectrum of familial inclusion body myopathies in 13 families and description of a quadriceps sparing phenotype in non-Iranian Jews
84. An Italian family with autosomal recessive quadriceps-sparing inclusion-body myopathy (ARQS-IBM) linked to chromosome 9p1
85. Hereditary inclusion body myopathy maps to chromosome 9p1-q1
86. Various types of hereditary inclusion body myopathies map to chromosome 9p1-q1
87. Fine-structure mapping of the hereditary inclusion body myopathy locus
88. The UDP-N-acetylglucosamine 2-epimerase/N-acetylmannosamine kinase gene is mutated in recessive hereditary inclusion body myopathy
89. Distal myopathy with rimmed vacuole formation: A follow-up study
90. Rimmed vacuolar distal myopathy: A clinical, electrophysiological, histopathological and computed tomographic study of seven cases
91. Rimmed vacuolar distal myopathy: An ultrastructural study
92. Gene locus for autosomal recessive distal myopathy with rimmed vacuoles maps to chromosome 9
93. Familial inclusion body myositis: Evidence for autosomal dominant inheritance
94. Neurogenic involvement in distal myopathy (Welander). Histochemical and morphological observations on muscle and nerve biopsies
95. Welander's distal myopathy: Clinical, neurophysiological and muscle biopsy observations in young and middle-aged adults with early symptoms
96. 'Inclusion body myositis-like' intranuclear filamentous inclusions in distal myopathy (Welander type)
97. Genetic linkage of Welander distal myopathy to chromosome 2p13
98. Assignment of the tibial muscular dystrophy locus to chromosome 2q31
99. The first European family with tibial muscular dystrophy outside the Finnish population
100. Secondary calpain3 deficiency in 2q-linked muscular dystrophy: Titin is the candidate gene
101. Tibial muscular dystrophy and late-onset distal myopathy are linked to the same locus on chromosome 2q
102. A distinctive autosomal dominant vacuolar neuromyopathy linked to 19p13
103. Autosomal dominant myopathy with congenital joint contractures, ophthalmoplegia and rimmed vacuoles
104. Dominant hereditary inclusion-body myopathy gene (IBM3) maps to chromosome region 17p13.1
105. A novel autosomal dominant distal myopathy with early respiratory failure: Clinico-pathologic characteristics and exclusion of linkage to candidate genetic loci
106. Clinical delineation and localization to chromosome 9p13.3-p12 of a unique dominant disorder in four families: Hereditary inclusion body myopathy, Paget disease of bone, and frontotemporal dementia
107. An inflammatory, familial, inclusion body myositis with autoimmune features and a phenotype identical to sporadic inclusion body myositis: Studies in 3 families
108. Multiple mitochondrial DNA deletions in hereditary inclusion body myopathy
109. Apolipoprotein E immunoreactive deposits in inclusion-body muscle
110. Apolipoprotein E and apolipoprotein E messenger RNA in muscle of inclusion-body myositis and myopathies
111. Light and electron microscopic immunolocalization of Presenilin 1 in abnormal muscle fibers of patients with sporadic inclusion-body myositis and autosomal-recessive inclusion-body myopathy
112. Novel immunolocalization of α-synuclein in human muscle of inclusion-body myositis, regenerating and necrotic muscle fibers, and at neuromuscular junctions
113. Apolipoprotein E type epsilon 4 allele frequency is not increased in patients with sporadic inclusion body myositis
114. Neurodegeneration-associated proteins and inflammation in sporadic inclusion-body myositis
115. Inclusion body myositis in HIV-1 and HTLV-1 infected patients
116. Inclusion body myositis: Atypical clinical presentations
117. Inclusion body myositis in post-poliomyelitis muscular atrophy
118. Increase of nitric oxide synthases and nitrotyrosine in inclusion-body myositis
119. Nitric oxide-induced oxidative stress in autosomal recessive and dominant inclusion-body myopathies
120. Amyloid-beta deposition in skeletal muscle of transgenic mice: Possible model of inclusion body myopathy
121. Transgenic mice over-expressing the C-99 fragment of betaPP with an alpha-secretase site mutation develop a myopathy similar to human inclusion body myositis